STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Byung-Hak | - |
dc.contributor.author | Lee, Haeri | - |
dc.contributor.author | Park, Cheol Gyu | - |
dc.contributor.author | Jeong, Ae Jin | - |
dc.contributor.author | Lee, Song-Hee | - |
dc.contributor.author | Noh, Kum Hee | - |
dc.contributor.author | Park, Jong Bae | - |
dc.contributor.author | Lee, Chung-Gi | - |
dc.contributor.author | Paek, Sun Ha | - |
dc.contributor.author | Kim, Hyunggee | - |
dc.contributor.author | Ye, Sang-Kyu | - |
dc.date.accessioned | 2021-08-31T08:32:58Z | - |
dc.date.available | 2021-08-31T08:32:58Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 2073-4409 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/57389 | - |
dc.description.abstract | Constitutively activated STAT3 plays an essential role in the initiation, progression, maintenance, malignancy, and drug resistance of cancer, including glioblastoma, suggesting that STAT3 is a potential therapeutic target for cancer therapy. We recently identified ODZ10117 as a small molecule inhibitor of STAT3 and suggested that it may have an effective therapeutic utility for the STAT3-targeted cancer therapy. Here, we demonstrated the therapeutic efficacy of ODZ10117 in glioblastoma by targeting STAT3. ODZ10117 inhibited migration and invasion and induced apoptotic cell death by targeting STAT3 in glioblastoma cells and patient-derived primary glioblastoma cells. In addition, ODZ10117 suppressed stem cell properties in glioma stem cells (GSCs). Finally, the administration of ODZ10117 showed significant therapeutic efficacy in mouse xenograft models of GSCs and glioblastoma cells. Collectively, ODZ10117 is a promising therapeutic candidate for glioblastoma by targeting STAT3. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | TUMOR-INITIATING CELLS | - |
dc.subject | GLIOMA STEM-CELLS | - |
dc.subject | SIGNAL TRANSDUCER | - |
dc.subject | CANCER | - |
dc.subject | IDENTIFICATION | - |
dc.subject | ACTIVATION | - |
dc.subject | TARGET | - |
dc.title | STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Hyunggee | - |
dc.identifier.doi | 10.3390/cells9030722 | - |
dc.identifier.scopusid | 2-s2.0-85089155701 | - |
dc.identifier.wosid | 000529337400199 | - |
dc.identifier.bibliographicCitation | CELLS, v.9, no.3 | - |
dc.relation.isPartOf | CELLS | - |
dc.citation.title | CELLS | - |
dc.citation.volume | 9 | - |
dc.citation.number | 3 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | TUMOR-INITIATING CELLS | - |
dc.subject.keywordPlus | GLIOMA STEM-CELLS | - |
dc.subject.keywordPlus | SIGNAL TRANSDUCER | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | TARGET | - |
dc.subject.keywordAuthor | glioblastoma | - |
dc.subject.keywordAuthor | glioma stem cell (GSC) | - |
dc.subject.keywordAuthor | ODZ10117 | - |
dc.subject.keywordAuthor | STAT3 | - |
dc.subject.keywordAuthor | targeted therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.